Wall Street brokerages forecast that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will announce earnings per share (EPS) of ($0.15) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Pieris Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.17) and the highest estimate coming in at ($0.13). Pieris Pharmaceuticals reported earnings of ($0.16) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 6.3%. The business is scheduled to report its next quarterly earnings results on Wednesday, November 14th.
On average, analysts expect that Pieris Pharmaceuticals will report full-year earnings of ($0.49) per share for the current fiscal year, with EPS estimates ranging from ($0.51) to ($0.44). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.77) per share, with EPS estimates ranging from ($0.95) to ($0.59). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Pieris Pharmaceuticals.
Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings data on Thursday, August 9th. The biotechnology company reported $0.00 EPS for the quarter, missing the consensus estimate of $0.01 by ($0.01). Pieris Pharmaceuticals had a negative net margin of 22.38% and a negative return on equity of 27.81%. The company had revenue of $11.69 million for the quarter, compared to the consensus estimate of $13.46 million.
Shares of PIRS traded down $0.10 during midday trading on Tuesday, hitting $5.20. 248,677 shares of the company traded hands, compared to its average volume of 375,564. Pieris Pharmaceuticals has a 52 week low of $4.43 and a 52 week high of $9.75.
In other news, Director Christopher P. Kiritsy acquired 5,000 shares of the firm’s stock in a transaction on Friday, September 14th. The stock was acquired at an average price of $5.11 per share, with a total value of $25,550.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $51,100. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.07% of the stock is owned by company insiders.
Several large investors have recently modified their holdings of the company. BlackRock Inc. increased its position in shares of Pieris Pharmaceuticals by 49.1% during the second quarter. BlackRock Inc. now owns 2,685,490 shares of the biotechnology company’s stock worth $13,616,000 after acquiring an additional 884,348 shares during the period. Acadian Asset Management LLC increased its position in shares of Pieris Pharmaceuticals by 45.5% during the second quarter. Acadian Asset Management LLC now owns 2,124,873 shares of the biotechnology company’s stock worth $10,773,000 after acquiring an additional 664,032 shares during the period. Aquilo Capital Management LLC purchased a new position in shares of Pieris Pharmaceuticals during the second quarter worth approximately $10,013,000. Millennium Management LLC increased its position in shares of Pieris Pharmaceuticals by 160.7% during the first quarter. Millennium Management LLC now owns 1,824,109 shares of the biotechnology company’s stock worth $12,440,000 after acquiring an additional 1,124,338 shares during the period. Finally, Prosight Management LP increased its position in shares of Pieris Pharmaceuticals by 141.2% during the second quarter. Prosight Management LP now owns 1,360,000 shares of the biotechnology company’s stock worth $6,895,000 after acquiring an additional 796,237 shares during the period. 64.89% of the stock is currently owned by institutional investors and hedge funds.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Featured Article: What is Compound Annual Growth Rate (CAGR)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.